Горбань Н. А.

ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской Федерации; Россия, 121359 Москва, ул. Маршала Тимошенко, 15

1. Netto G.J., Amin M.B., Kench J.G. et al. Chapter 4: Tumours of the Prostate. In: WHO Classification of Tumours: Urinary and Male Genital Tumours. Lyon: International Agency for Research on Cancer, 2022. Available at: https://tumourclassification.iarc. who.int/chapters/36.

2. Eble J.N.S.G., Epstein J.I., Sesterhenn I.A. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004.

3. Moch H.H.P., Ulbright T.M., Reuter V. The WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2016.

4. Humphery H.A. Prostate Pathology. Chicago: ASCP-Press, 2003. P. 556.

5. Kench J.G., Amin M.B., Berney D.M. et al. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology 2022;81:447–58. DOI: 10.1111/his.14711.

6. Kaur H.B., Salles D.C., Paulk A. et al. PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations. Histopathology 2021;78:327–33.

7. Seipel A.H., Delahunt B., Samaratunga H. et al. Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology 2014;65:216–27.

8. Epstain J.I., Netto G.J. Biopsy Interpretation of the Prostate. Lippincott Williams & Wilkins, 2008. 358 p.

9. Bostwick D.G., Cheng L. Precursors of prostate cancer. Histopathology 2012;60(1):4–27. DOI: 10.1111/j.1365-2559.2011.04007.x

10. Varma M., Egevad L., Algaba F. et al. Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. J Clin Pathol 2016;69:852–7. DOI: 10.1136/ jclinpath-2016-203658

11. Khani F., Wobker S.E., Hicks J.L. et al. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J Pathol 2019;249:79–89.

12. Kimura K., Tsuzuki T., Kato M. et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 2014;74:680–7.

13. Miyai K., Divatia M.K., Shen S.S. et al. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. Hum Pathol 2014;45:1572–81.

14. Epstein J.I., Egevad L., Amin M.B. et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244–52.

15. Samaratunga H., Delahunt B., Egevad L. et al. Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology 2020;52:192–6.

16. Van Leenders G., van der Kwast T.H., Grignon D.J. et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 2020;44:e87–e99.

17. Epstein J.I., Amin M.B., Fine S.W. et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med 2021;145:461–93.

18. Rijstenberg L.L., Hansum T., Hollemans E. et al. Intraductal carcinoma has a minimal impact on grade group assignment in prostate cancer biopsy and radical prostatectomy specimens. Histopathology 2020;77:742–8.

19. Hickman R.A., Yu H., Li J. et al. Atypical intraductal cribriform proliferations of the prostate exhibit similar molecular and clinicopathologic characteristics as intraductal carcinoma of the prostate. Am J Surg Pathol 2017;41:550–6.

20. Dong F., Yang P., Wang C. et al. Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol 2013;37:1855–61.

21. Shah R.B., Cai Q., Aron M. et al. Diagnosis of “cribriform” prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. Am J Cancer Res 2021;11:3990–4001.

22. Egevad L., Delahunt B., Kristiansen G. et al. Contemporary prognostic indicators for prostate cancer incorporating international society of urological pathology recommendations. Pathology 2018;50:60–73.

23. Conteduca V., Oromendia C., Eng K.W. et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer 2019;121;7–18.

24. Bishop J.A., Yonescu R., Epstein J.I., Westra W.H. A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma. Hum Pathol 2015;46;1204–8.

25. Magers M.J., Iczkowski K.A., Montironi R. et al. MYB–NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. Mod Pathol 2019;32:1666–74.

26. Simper N.B., Jones C.L., MacLennan G.T. et al. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. Hum Pathol 2015;46:805–12.

27. West R.B., Kong C., Clarke N. et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 2011;35:92–9.